Clinical Trial Update: A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating durvalumab with or without tremelimumab in endometrial cancer and carcinosarcoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Endometrial Cancer Recurrent
• Endometrial Carcinoma
• Endometrial Carcinoma Recurrent
• Endometrial Carcinosarcoma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Endometrial Cancer, Endometrial Carcinosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2024-02-06